Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Withdrawn 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Lymphoid 1Gastrointestinal 1Dermatologic 1CNS 1

Conditions

Colorectal Neoplasms 1422Pancreatic Neoplasms 847Carcinoma, Hepatocellular 736Stomach Neoplasms 639Colonic Neoplasms 441Rectal Neoplasms 400Esophageal Neoplasms 395Carcinoma, Non-Small-Cell Lung 328Breast Neoplasms 328Neoplasms 300Liver Neoplasms 280Cholangiocarcinoma 242Ovarian Neoplasms 240Lung Neoplasms 238Neoplasm Metastasis 237Gastrointestinal Neoplasms 216Melanoma 184Prostatic Neoplasms 162Esophageal Squamous Cell Carcinoma 160Biliary Tract Neoplasms 160Endometrial Neoplasms 141Squamous Cell Carcinoma of Head and Neck 128Uterine Cervical Neoplasms 127Carcinoma, Renal Cell 113Head and Neck Neoplasms 112Sarcoma 100Urinary Bladder Neoplasms 95Adenocarcinoma Of Esophagus 89Triple Negative Breast Neoplasms 84Anus Neoplasms 83

Interventions

Specimen Handling 1Nivolumab 1Ipilimumab 1CTLA-4 Antigen 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Xeroderma Pigmentosum × Gastrointestinal × 1 year × Clear all
NCT04500548 2025-09-10

Testing the Combination of Two Immunotherapy Drugs (Nivolumab and Ipilimumab) in Children, Adolescent, and Young Adult Patients With Relapsed/Refractory Cancers That Have an Increased Number of Genetic Changes, The 3CI Study

National Cancer Institute (NCI)

Phase 1 Withdrawn
CNSGastrointestinalLymphoidOther hematologic neoplasm

Turcot syndrome, Colorectal Neoplasms, Hereditary Nonpolyposis, Lymphoma, Neuroblastoma, Xeroderma Pigmentosum, Central Nervous System Neoplasms, Hematologic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡